Understanding the implications of sarcopenia in heart failure using multi-modality imaging and genetics

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 17, 2029
Response Due
Active
Status

Opportunity Overview

Heart failure (HF) is a condition that occurs due to the heart not efficiently pumping blood around the body. It is a major cause of disability and death worldwide. A growing area of research is the link between HF and sarcopenia, which is the gradual loss of muscle mass and strength. Sarcopenia is usually thought of as an ageing problem, but it is now recognised in up to 1 in 3 people with HF. This overlap matters because the relationship goes both ways. On the one hand, HF leads to inflammation, hormonal changes, and metabolic problems that promote muscle wasting. On the other hand, sarcopenia worsens frailty, reduces physical activity, and doubles the risk of dying within a year for HF patients. In short, sarcopenia is not just a consequence of HF—it may actively make the disease worse.
 
Muscles in the legs, such as the quadriceps, carry the body’s weight and weaken through loss of muscle mass early in illness. By contrast, chest muscle mass, though still related to leg muscles, may serve as a more stable indicator of illness. Among them, the pectoralis major muscle has emerged as a particularly promising indicator of overall muscle health and heart function. Research shows that the size of this muscle, measured using routine chest scans, is strongly linked to survival in people with and without HF.
 
Currently, there are major limitations in how sarcopenia is measured. Common techniques, such as bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DEXA) scans, only provide indirect estimates of muscle mass, mostly in the arms and legs. These methods can be inaccurate in people with HF because they often have swelling of their extremities which can distort measurements. Conversely, magnetic resonance imaging (MRI) or computed tomography (CT) scans both provide a direct and precise way to measure muscle mass. As it stands, muscle analysis is not yet standardised within routine heart or chest scans, meaning that valuable...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
Procurement stageActive solicitation
Response dueSeptember 17, 2029
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.